ReviewFrontiers in immunology2026

Hypomethylating agents are the current therapy backbone for MDS and AML relapsing after allogeneic hematopoietic stem cell transplantation.

Guido Kobbe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.